Corvus Pharmaceuticals, Inc. (CRVS) Income Statement Analysis

See more : Suzhou Mingzhi Technology Co., Ltd. (688355.SS) Income Statement Analysis – Financial Results

Complete financial analysis of Corvus Pharmaceuticals, Inc. (CRVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corvus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Genesis Growth Tech Acquisition Corp. (GGAAU) Income Statement Analysis – Financial Results
JMT Auto Limited (JMTAUTOLTD.NS) Income Statement Analysis – Financial Results
Hong Leong Bank Berhad (5819.KL) Income Statement Analysis – Financial Results
Andean Precious Metals Corp. (APM.V) Income Statement Analysis – Financial Results
Shanghai Anoky Group Co., Ltd (300067.SZ) Income Statement Analysis – Financial Results

Corvus Pharmaceuticals, Inc. (CRVS)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.corvuspharma.com

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	151.00K	367.00K	460.00K	632.00K	743.00K	847.00K	842.00K	594.00K	148.00K	0.00
Gross Profit	-151.00K	-367.00K	-460.00K	-632.00K	-743.00K	-847.00K	-842.00K	-594.00K	-148.00K	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	16.53M	24.47M	29.12M	31.83M	37.98M	38.59M	46.31M	29.36M	11.35M	41.46K
General & Administrative	6.88M	8.10M	9.52M	11.93M	10.88M	10.64M	10.22M	7.62M	2.42M	134.18K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	6.88M	8.10M	9.52M	11.93M	10.88M	10.64M	10.22M	7.62M	2.42M	134.18K
Other Expenses	0.00	587.00K	235.00K	37.46M	0.00	0.00	0.00	0.00	-17.60M	0.00
Operating Expenses	23.41M	32.57M	38.63M	43.76M	48.85M	49.22M	56.52M	36.98M	13.77M	175.64K
Cost & Expenses	23.41M	32.57M	38.63M	43.76M	48.85M	49.22M	56.52M	36.98M	13.77M	175.64K
Interest Income	0.00	654.00	0.00	540.00K	2.18M	2.28M	861.00K	601.00K	35.00K	0.00
Interest Expense	1.58M	654.00K	15.00K	540.00K	2.18M	2.28M	0.00	601.00K	0.00	0.00
Depreciation & Amortization	151.00K	367.00K	460.00K	632.00K	743.00K	847.00K	842.00K	594.00K	148.00K	175.64K
EBITDA	-26.88M	-40.94M	-42.78M	-5.36M	-48.85M	-46.09M	-54.82M	-35.78M	-31.19M	14.64K
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-23.41M	-32.57M	-38.63M	-43.76M	-48.85M	-49.22M	-56.52M	-36.98M	-13.77M	-175.64K
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-3.62M	-8.74M	-4.61M	37.77M	2.18M	2.28M	861.00K	601.00K	-17.57M	0.00
Income Before Tax	-27.03M	-41.31M	-43.24M	-6.00M	-46.67M	-46.94M	-55.66M	-36.38M	-31.34M	-175.64K
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	8.74M	-5.04M	-1.17M	-2.93M	2.28M	-842.00K	-594.00K	-35.00K	0.00
Net Income	-27.03M	-50.05M	-38.20M	-4.82M	-43.75M	-46.94M	-55.66M	-36.38M	-31.34M	-175.64K
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.56	-1.08	-0.91	-0.16	-1.49	-1.71	-2.72	-2.36	-1.54	-1.03
EPS Diluted	-0.56	-1.08	-0.91	-0.16	-1.49	-1.71	-2.72	-2.36	-1.54	-1.03
Weighted Avg Shares Out	48.03M	46.55M	41.85M	29.48M	29.35M	27.51M	20.49M	15.42M	20.41M	170.00K
Weighted Avg Shares Out (Dil)	48.03M	46.55M	41.85M	29.48M	29.35M	27.51M	20.49M	15.42M	20.41M	170.28K

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

March 5, 2021globenewswire.com

BURLINGAME, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will participate in two upcoming investor conferences in March:

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

February 20, 2021benzinga.com

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

February 17, 2021globenewswire.com

BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its common stock, which includes 1,212,231 shares of common...

Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today

February 12, 2021benzinga.com

Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company.

Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

February 12, 2021globenewswire.com

BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of $3.50...

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock

February 11, 2021globenewswire.com

BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in...

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

February 4, 2021globenewswire.com

Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory failure

Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition

December 6, 2020globenewswire.com

Updated interim d ata from CPI-818 's p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas

Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exposition

November 30, 2020globenewswire.com

Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS)